Pharmolix Inc. — A Leader in Multimodal Foundation Models and Intelligent Agent Platforms for Biopharmaceuticals
At PharMolix, we combine drug discovery expertise with multimodal biomedical foundation models and intelligent agents to advance our proprietary pipeline. Our ChatDD platform enables researchers to work with AI agents to understand disease biology and develop drug candidates. Expert judgment and experimental feedback guide each round of molecular design and optimization. Our programs focus on autoimmune diseases and cancer, with the goal of developing differentiated therapies that address unmet clinical needs.
In our first proprietary program, we nominated a preclinical candidate (PCC) with first-in-class potential just seven months after initiation of the project. Through an iterative design–test–learn process, experimental results guide each new round of molecular design and optimization. This approach helps us advance our drug programs while continuously refining our AI platform.
| Asset | Stage |
|---|---|
| SMT001PCC | |
| SMT002Lead Optimization | |
| SMT003Lead Discovery | |
| SMT004Lead Discovery |
Bispecific AbLupus Nephritis
Bispecific proTCEOvarian Cancer
Trispecific AbAutoimmune Disease
Bispecific proTCEBreast Cancer
ChatDD combines expert knowledge with multimodal biomedical foundation models and AI agents. Researchers guide tasks and refine results through natural language.
Bring industry data and internal knowledge together to answer your team's research questions. AI agents work together to analyze targets, drugs, pipelines, and patents. Their reports inform program evaluation, R&D planning, and business development decisions.
Turn goals and constraints expressed in natural language into molecular design tasks. AI agents coordinate specialized models and computational tools for antibody design, docking, and candidate evaluation. Expert judgment and experimental feedback guide each round of optimization.
Streamline medical writing for clinical development and regulatory submissions. AI agents help teams interpret source materials and prepare drafts of trial protocols, clinical study reports, and other relevant documents. Teams review and edit the drafts online before qualified professionals finalize the content.
Relationships spanning drug–target interactions, therapeutic indications, and target–disease associations.
High-quality text chunks linked to the graph from research papers, conference materials, and other authoritative sources.
Entities from authoritative sources, including drug targets, diseases, companies, and other key biomedical entities.
